216 related articles for article (PubMed ID: 30679762)
1. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
[TBL] [Abstract][Full Text] [Related]
2. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Vihervuori VJ; Lahtela J; Talala K; Taari K; Tammela TL; Auvinen A
Br J Cancer; 2018 May; 118(9):1248-1254. PubMed ID: 29563633
[TBL] [Abstract][Full Text] [Related]
3. Tumor features and survival after radical prostatectomy among antidiabetic drug users.
Joentausta RM; Kujala PM; Visakorpi T; Tammela TL; Murtola TJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):367-373. PubMed ID: 27502739
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
8. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
10. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
11. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
12. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
13. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
15. Hyperglycemia, Classified with Multiple Biomarkers Simultaneously in Men without Diabetes, and Risk of Fatal Prostate Cancer.
Marrone MT; Selvin E; Barber JR; Platz EA; Joshu CE
Cancer Prev Res (Phila); 2019 Feb; 12(2):103-112. PubMed ID: 30538098
[TBL] [Abstract][Full Text] [Related]
16. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
[TBL] [Abstract][Full Text] [Related]
17. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.
Macleod LC; Chery LJ; Hu EY; Zeliadt SB; Holt SK; Lin DW; Porter MP; Gore JL; Wright JL
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):190-5. PubMed ID: 25823651
[TBL] [Abstract][Full Text] [Related]
19. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer.
Wright JL; Plymate SR; Porter MP; Gore JL; Lin DW; Hu E; Zeliadt SB
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):204-8. PubMed ID: 23459096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]